Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice

Clinical Cancer Research

Volumn 18, Issue 20, 2012, Pages 5628-5638

  Fan, Haitao ^a   Zhang, Ian ^c   Chen, Xuebo ^b   Zhang, Leying ^c   Wang, Huaqing ^a   Da Fonseca, Anna ^d   Manuel, Edwin R ^c   Diamond, Don J ^c   Raubitschek, Andrew ^c   Badie, Behnam ^c  

^a SHANDONG UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; SINGLE WALLED NANOTUBE; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; BRAIN CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CANCER SURVIVAL; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; FEMALE; FLOW CYTOMETRY; IN VIVO STUDY; LOW DRUG DOSE; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BRAIN NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; HUMANS; IMMUNOTHERAPY; MELANOMA; MICE; NANOTUBES, CARBON; NEOPLASMS, EXPERIMENTAL; OLIGODEOXYRIBONUCLEOTIDES; TISSUE DISTRIBUTION;

EID: 84867569548     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1911     Document Type: Article

References (28)

1. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011;11:352-63.
2. Galea I, Bechmann I, Perry VH. What is immune privilege (not)? Trends Immunol 2007;28:12-8. (Pubitemid 44960159)
3. Prins RM, Shu CJ, Radu CG, Vo DD, Khan-Farooqi H, Soto H, et al. Anti-tumor activity and traf ficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother 2008;57:1279-89.
4. Hickey MJ, Malone CC, Erickson KL, Jadus MR, Prins RM, Liau LM, et al. Cellular and vaccine therapeutic approaches for gliomas. J Transl Med 2010;8:100.
5. Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol 2006;10:133-46. (Pubitemid 351976185)
6. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 2006;8:60-6. (Pubitemid 43154452)
7. Dalpke AH, Schafer MK, Frey M, Zimmermann S, Tebbe J, Weihe E, et al. Immunostimulatory CpG-DNA activates murine microglia. J Immunol 2002;168:4854-63. (Pubitemid 34495946)
8. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006;54:526-35. (Pubitemid 44449333)
9. Jahrsdorfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008;3:27-32. (Pubitemid 351410539)
10. Weber JS, Zarour H, Redman B, Trefzer U, O'Day S, van den Eertwegh AJ, et al. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer 2009;115:3944-54.
11. Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrie M, et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 2010;12:401-8.
12. Zhao D, Alizadeh D, Zhang L, Liu W, Farrukh O, Manuel E, et al. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin Cancer Res 2011;17:771-82.
13. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 2006;312:1027-30.
14. Liu Z, Tabakman SM, Chen Z, Dai H. Preparation of carbon nanotube bioconjugates for biomedical applications. Nat Protoc 2009;4:1372-82.
15. Alizadeh D, Zhang L, Brown CE, Farrukh O, Jensen MC, Badie B. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin Cancer Res 2010;16:3399-408.
16. Manuel ER, Blache CA, Paquette R, Kaltcheva TI, Ishizaki H, Ellenhorn JD, et al. Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. Cancer Res 2011;71:4183-91.
17. Alizadeh D, Zhang L, Hwang J, Schluep T, Badie B. Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas. Nanomedicine 2010;6:382-90.
18. VanHandel M, Alizadeh D, Zhang L, Kateb B, Bronikowski M, Manohara H, et al. Selective uptake of multi-walled carbon nanotubes by tumor macrophages in a murine glioma model. J Neuroimmunol 2009;208:3-9.
19. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 2010;40:2969-75.
20. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
21. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998;88:11-20. (Pubitemid 28018958)
22. de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 1983;43:3427- 33.
23. Lonser RR, Song DK, Klapper J, Hagan M, Auh S, Kerr PB, et al. Surgical management of melanoma brain metastases in patients treated with immunotherapy. J Neurosurg 2011;115:30-6.
24. Volovitz I, Marmor Y, Azulay M, Machlenkin A, Goldberger O, Mor F, et al. Split immunity: immune inhibition of rat gliomas by subcutaneous exposure to unmodified live tumor cells. J Immunol 2011;187:5452-62.
25. Larocque D, Sanderson NS, Bergeron J, Curtin JF, Girton J, Wibowo M, et al. Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology. Proc Natl Acad Sci U S A 2010;107:14443-8.
26. Pellegatta S, Poliani PL, Stucchi E, Corno D, Colombo CA, Orzan F, et al. Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro Oncol 2010;12:377-88.
27. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005;11:4160-7. (Pubitemid 40791581)
28. Liu Z, Davis C, Cai W, He L, Chen X, Dai H. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci U S A 2008;105:1410-5. (Pubitemid 351346531)